HIGHLIGHTS
- who: Rafael Amorim Belo Nunes from the China Medical University of Vienna, Austria have published the research work: Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network, in the Journal: (JOURNAL) of 30/08/2021
- what: The authors aimed to evaluate the 5year incidence and compare the ratios of significant cardiovascular outcomes in patients with CML without a past history of heart or cerebrovascular diseases treated with Bcr-ABL TKIs imatinib, dasatinib, or nilotinib, using data from . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.